Genentech, Inc. (Genentech) is one of the world’s leading biotech companies. The company undertakes research, development, manufacture, and marketing of biotherapeutics. Genentech focuses on developing drugs for unmet medical needs in the areas of cancer, immunological diseases and angiogenic disorders. Some of its major products include Rituxan, Avastin, Herceptin, Tarceva, Lucentis, Xolair, Pulmozyme and Activase. Its research activities focus on areas of cancer, metabolism, immunology, infectious disease and neuroscience. Its clinical development pipeline includes small molecules, monoclonal antibodies, and antibody drug conjugates. The company operates as a wholly owned subsidiary of Roche following its acquisition in 2009. The company is headquartered in South San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Genentech, Inc.
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=247686
Table of Contents
List of Tables 4
List of Figures 5
Genentech, Inc. Company Snapshot 6
Genentech, Inc. Company Overview 6
Key Information 6
Genentech, Inc. Pipeline Products and Clinical Trials Overview 7
Genentech, Inc. – Pipeline Analysis Overview 10
Business Description 10
Key Facts 10
Genentech, Inc. – Major Products and Services 11
Genentech, Inc. Pipeline Products by Development Stage 13
Genentech, Inc. Pipeline Products Overview 16
Akt Inhibitor Companion Diagnostic Assay 16
Akt Inhibitor Companion Diagnostic Assay Product Overview 16
Anti-HER3/EGFR DAF Mab Companion Diagnostic Assay 17
Anti-HER3/EGFR DAF Mab Companion Diagnostic Assay Product Overview 17
Anti-IL17 Mab Companion Diagnostic Assay 18
Anti-IL17 Mab Companion Diagnostic Assay Product Overview 18
For More Information Kindly Contact:
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States – 12207
USA-Canada Toll Free: 866-997-4948
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/